Bio
Tiffany Olson currently serves as a Board Member for Castle Biosciences, Telix Pharmaceuticals, Mimedx, Education & Research Foundation for Nuclear Medicine, and Molecular Imaging, and on the Langham Logistics Advisory board. Other boards have included Asuragen, BioTelemetry Inc, ThermoGenesis, Little Rapids Corporation and Chairwoman of Diaceutics. She is a thought leader in the healthcare industry, with significant experience leading healthcare innovation in several industry segments.
Expertise
Tiffany was formerly the president of Nuclear & Precision Health Solutions at Cardinal Health which develops, manufactures, compounds, dispenses and delivers radiopharmaceuticals. Prior to Cardinal Health, Tiffany was President of NaviMed, a company focused on personalizing medicine through innovative diagnostics. She also worked for Eli Lilly and Company, where she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics. Tiffany worked for Roche Diagnostics for many years, where she attained the position of President and CEO of Roche Diagnostics Corporation. Prior to this appointment, Tiffany was the Global Head of Market Development and Quality located in Basel, Switzerland. Other positions she held with the company included Vice President of Roche Molecular Diagnostics and Vice President of Corporate Accounts.
